Retatrutide: Research Overview

The short version

Retatrutide (LY3437943) is an investigational once-weekly injectable drug being studied by Eli Lilly for obesity, type 2 diabetes, and fatty liver disease. It simultaneously activates three receptors: GLP-1R, GIPR, and the glucagon receptor. In a 48-week Phase 2 obesity trial with 338 adults, the highest-dose group lost a mean of 24.2% of body weight versus 2.1% with placebo ^[16]. A separate Phase 2 trial in 281 adults with type 2 diabetes showed HbA1c reduced by 2.02% and body weight by 16.94% at 36 weeks ^[17].

Retatrutide is not approved by the FDA or any regulator as of mid-2026. It is available only through registered clinical trials. Material sold through gray-market research channels cannot be verified for identity, purity, or sterility. "GLP-3" is a common misnomer for this compound — it is not accurate and should not be used. This page describes published clinical evidence only.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid acylation that enables albumin binding and supports a once-weekly injection schedule. Its molecular formula is C221H342N46O68 (free acid). It is distinct from GLP-1 single agonists and GIP/GLP-1 dual agonists by virtue of the added glucagon receptor activity — hence the GIP/GLP-1/glucagon triple-agonist designation ^[13].

Cryo-EM structural studies resolved retatrutide simultaneously bound to all three receptors. Its relative potency compared to native hormones is approximately 8.9-fold at GIPR (more potent than native GIP), 0.4-fold at GLP-1R, and 0.3-fold at GCGR ^[14]. The partial glucagon agonism is deliberate: full glucagon agonism would raise blood sugar, so the modulated level adds energy expenditure without the adverse glucose effect.

How it works

The three receptor arms contribute differently to the compound's effects ^[13][14]:

• GLP-1R agonism slows gastric emptying, reduces appetite, and augments glucose-dependent insulin secretion.
• GIPR agonism further enhances glucose-dependent insulin secretion; the GIPR arm at higher-than-native potency appears to amplify the weight-loss effect beyond what GLP-1 single agonists achieve.
• Glucagon receptor agonism (at partial, controlled activity) increases energy expenditure through hepatic lipid oxidation and thermogenic mechanisms — the additional engine driving larger fat loss than dual-agonist approaches.

The combination of appetite suppression, improved insulin sensitivity, and increased energy expenditure is what produces the larger and faster weight-loss signal seen in Phase 2 compared to prior incretin classes ^[13].

What the research shows

Phase 2 obesity trial (48 weeks, n=338 adults): Mean body-weight change at 48 weeks was -24.2% at 12 mg versus -2.1% for placebo. GI adverse events (nausea, diarrhea, vomiting, constipation) were dose-related and mostly mild to moderate. A dose-dependent heart-rate increase was observed, peaking around 24 weeks ^[16].

Phase 2 obesity substudy — fatty liver disease (MASLD, n=98 with >=10% liver fat, 24–48 weeks): Relative liver-fat change at 24 weeks was -82.4% at 12 mg versus +0.3% for placebo; 86% of participants at 12 mg reached normal liver-fat levels (below 5%). Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[15].

Phase 2 type 2 diabetes trial (36 weeks, n=281): HbA1c fell by 2.02% with 12 mg versus 0.01% for placebo at 24 weeks. Body weight fell by 16.94% versus 3.00% for placebo at 36 weeks. No severe hypoglycemia, no deaths reported ^[17].

Structural pharmacology: Cryo-EM structures of retatrutide bound to all three receptors were resolved at 2.68–3.26 Angstrom resolution, confirming simultaneous tri-agonism ^[14].

Phase 3 program: The TRIUMPH-1/2/3 trials and dedicated cardiovascular and kidney outcomes trials are ongoing; no Phase 3 results have been published as of mid-2026 ^[13].

Reported effects, cautions, and safety

What people in research-use communities report (anecdotal, not clinical evidence): Community reporters consistently describe near-total suppression of food cravings — what they call "food noise going quiet." Rapid and pronounced weight reduction is frequently reported, described as qualitatively faster than experiences with other incretin-class compounds. Increased body warmth or a mild thermogenic sensation is attributed to glucagon receptor activity. Elevated resting heart rate, nausea (especially in the first weeks or after escalation), sulfur burps, fatigue, and constipation are the most common adverse reports. Some describe sleep disturbance early on; others report mood uplift or improved relationship with food. None of these reports involve verified doses or clinical oversight.

Safety cautions from the published clinical literature:

• Unverified gray-market material: Retatrutide obtained outside clinical trials has no confirmed identity, purity, or sterility. The FDA has issued warning letters to gray-market vendors ^[16].
• GI adverse events: Nausea affected up to 45% of participants at the highest Phase 2 dose and drove an 18% discontinuation rate. Unmonitored use carries heightened risk of severe GI events and dehydration.
• Dose-dependent heart-rate increase: Phase 2 data showed mean HR increases of ~5–7 bpm at the highest doses, peaking around 24 weeks. The glucagon receptor arm drives cardiac chronotropy via cAMP/PKA ^[16].
• Lean-mass reduction: Phase 2 body-composition data confirmed absolute lean-mass reduction alongside fat loss; without adequate protein and resistance exercise, rapid weight loss may disproportionately erode muscle.
• Drug interactions: Combined use with insulin or sulfonylureas may substantially increase hypoglycemia risk given the glucose-dependent insulin augmentation ^[17].
• Long-term unknowns: All pivotal cardiovascular and renal outcomes trials are ongoing; no long-term data exist.

Where it fits in the research landscape

Retatrutide is the outlier on this desk in terms of evidence maturity — it has the most robust and recent human clinical data of any compound here, with three Phase 2 trials published and Phase 3 ongoing. It is also the only compound on this desk that is a genuine investigational drug in a major pharmaceutical development program, not a research peptide distributed through non-regulated channels.

It represents a different category of research entirely from BPC-157 or GHK-Cu: sophisticated incretin pharmacology, large well-designed trials, and a near-approval timeline — pending outcomes from Phase 3.